Clinical Trial

SentientLight Seeks US$10M After Peer-Reviewed PEMF Study Validates Non-Drug Pain Relief

Funding to scale PEMF device production, complete FDA submission, continue clinical studies, and launch targeted digital marketing initiatives. HAYDEN, Idaho,…

4 months ago

Plug and Play Topeka Selects New Cohort of Nine Animal Health Startups for Accelerator Program

Emerging companies from six countries begin the 18-week startup program in Kansas' capital city TOPEKA, Kan., Aug. 13, 2025 /PRNewswire/ -- In…

4 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation…

4 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation…

4 months ago

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on…

4 months ago

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on…

4 months ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)…

4 months ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)…

4 months ago

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations –…

4 months ago

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations –…

4 months ago